

American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1.

Title: American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1.

Publication year: 2021

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Authors: University of Alabama at Birmingham.

Society: European Respiratory Society

Origin country: International (Europe)

Target countries: Europe

DOI: 10.1002/art.41734

PMID: 33728796

Source: <https://pubmed.ncbi.nlm.nih.gov/33728796/>

Arthritis Rheumatol Arthritis Rheumatol 3812 phebblackwell 101623795 ART Arthritis & Rheumatology (Hoboken, N.J.) 2326-5191 2326-5205 pmc-is-collection-domain yes pmc-collection-title Wiley - PMC COVID-19 Collection PMC8250724 PMC8250724.1 8250724 8250724 33728796 10.1002/art.41734 ART41734 1 Full Length Special Articles American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1 Curtis Jeffrey R. <https://orcid.org/0000-0002-8907-8976> 1 jrcurtis@uabmc.edu Johnson Sindhu R. <https://orcid.org/0000-0003-0591-2976> 2 Anthony Donald D. 3 Arasaratnam Reuben J. 4 Baden Lindsey R. 5 Bass Anne R. <https://orcid.org/0000-0002-3225-8351> 6 Calabrese Cassandra 7 Gravallese Ellen M. 5 Harpaz Rafael 8 Sadun Rebecca E. 9 Turner Amy S. <https://orcid.org/0000-0001-7695-2022> 10 Williams Eleanor Anderson 11 Mikuls Ted R. <https://orcid.org/0000-0002-0897-2272> 12 1 University of Alabama at Birmingham 2 Toronto Western Hospital Mount Sinai Hospital, and University of Toronto Toronto Ontario Canada 3 Louis Stokes Cleveland VA Medical Center MetroHealth Medical Center, and Case Western Reserve University Cleveland Ohio 4 VA North Texas Health Care System and University of Texas Southwestern Medical Center Dallas 5 Brigham and Women's Hospital Boston Massachusetts 6 Hospital for Special Surgery and Weill Cornell Medicine New York New York 7 Cleveland Clinic Cleveland Ohio 8 Harpaz Herman Consultants Atlanta Georgia 9 Duke University Durham North Carolina 10 American College of Rheumatology Atlanta Georgia 11 The Permanente Medical Group Union City California 12 University of Nebraska Medical Center and VA Nebraska-Western Iowa Health Care System Omaha * Address correspondence to Jeffrey R. Curtis, MD, MS, MPH, University of Alabama at Birmingham, FOT 802, 510 20th Street South, Birmingham, AL 35294. Email: jrcurtis@uabmc.edu . 24 5 2021 7 2021 73 7 384951 10.1002/art.v73.7 1093 1107 10 2 2021 10 3 2021 02 07 2021 02 07 2021 01 04 2024 © 2021, American College of Rheumatology This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. Objective To provide guidance to rheumatology providers on the use of coronavirus disease 2019 (COVID-19) vaccines for patients with rheumatic and musculoskeletal diseases (RMDs).

A task force was assembled that included 9 rheumatologists/immunologists, 2 infectious disease specialists, and 2 public health physicians. After agreeing on scoping questions, an evidence report was created that summarized the published literature and publicly available data regarding COVID-19 vaccine efficacy and safety, as well as literature for other vaccines in RMD patients. Task force members rated their agreement with draft consensus statements on a 9-point numerical scoring system, using a modified Delphi process and the RAND/University of California Los Angeles Appropriateness Method, with refinement and iteration over 2 sessions. Consensus

was determined based on the distribution of ratings.

Despite a paucity of direct evidence, 74 draft guidance statements were developed by the task force and agreed upon with consensus to provide guidance for use of the COVID-19 vaccines in RMD patients and to offer recommendations regarding the use and timing of immunomodulatory therapies around the time of vaccination.

These guidance statements, made in the context of limited clinical data, are intended to provide direction to rheumatology health care providers on how to best use COVID-19 vaccines and to facilitate implementation of vaccination strategies for RMD patients.

pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes
pmc-prop-open-access no pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed
no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no
pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no
pmc-prop-preprint no pmc-prop-in-epmc yes source-schema-version-number 2.0 cover-date July
2021 details-of-publishers-converter Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.4
mode:remove_FC converted:02.07.2021 Supported by the American College of Rheumatology.

Dr. Curtis has received consulting fees, speaking fees, and/or honoraria from AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Eli Lilly, and Novartis (less than \$10,000 each) and from Amgen, Janssen, Pfizer, Myriad, and Sanofi (more than \$10,000 each) and research grants from Genentech, Gilead, AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Eli Lilly, Amgen, Janssen, Pfizer, Myriad, and Sanofi. Dr. Johnson has received consulting fees, speaking fees, and/or honoraria from Ikarai and Boehringer Ingelheim (less than \$10,000 each) and research grants from Bayer, Boehringer Ingelheim, Corbus, and GlaxoSmithKline. Dr. Baden has received salary support from the New England Journal of Medicine (less than \$10,000). Dr. Calabrese has received consulting fees, speaking fees, and/or honoraria from AbbVie and Sanofi Genzyme (less than \$10,000 each). Dr. Gravalles has received salary support from the New England Journal of Medicine (more than \$10,000). Dr. Mikuls has received consulting fees, speaking fees, and/or honoraria from Sanofi, Horizon, Pfizer, and Gilead (less than \$10,000 each) and research support from Bristol Myers Squibb and Horizon. No other disclosures relevant to this article were reported.